OUR SCIENTIFIC ADVISORY BOARD
Timothy F. Jamison, Ph.D
Co-Founder and Scientific Advisor
A world-renowned expert in flow chemistry, methodology development, and organic synthesis, Tim Jamison founded Snapdragon Chemistry with a vision to enhance the entire drug discovery >> development >> manufacturing value chain through flow chemistry. With a career spanning over 15 years as a Professor of Chemistry at the Massachusetts Institute of Technology (MIT), including as Department Head of Chemistry, Tim has advanced the organic chemistry field with over 125 academic publications. Tim is also a key scientific leader in the Novartis-MIT Center for Continuous Manufacturing, where he makes fundamental contributions to the initiative with his expertise in flow chemistry. In addition, he has worked with numerous pharmaceutical companies to solve some of their most difficult chemistry challenges that arise in their drug discovery/development efforts.
Aaron B. Beeler, PhD
Co-Founder and Synthetic Technologies Advisor
Aaron Beeler is an Assistant Professor of Chemistry at Boston University and, prior to that, was Associate Director of the Center for Chemical Methodology and Library Development at Boston University. Aaron has authored 31 publications and has 2 patents. In addition, he has made fundamental contributions to flow chemistry and medicinal chemistry and shares in the same vision as Tim of transforming drug discovery/development through flow chemistry. Aaron’s research has contributed considerably to the development of unique reactor designs in flow chemistry and has enabled, among other things, photochemistry to create unique building blocks that greatly expand the medicinal chemists’ toolkit for discovering more effective medicines.
Christopher J. Welch, PhD
Christopher J. Welch is Chief Scientific Officer for Welch Innovation, LLC, an independent research and consulting firm located in Cranbury, NJ USA. Dr. Welch has worked in a variety of fields within the chemical industry, including discovery synthesis of agrochemicals (Velsicol-Sandoz), development of reagents for improved immunodiagnostic assays (Abbott Laboratories), development and commercialization of chromatographic stationary phases, reagents and enantioselective catalysts within a small chemical business environment (Regis Technologies) and the invention and application of new purification, analysis and high throughput experimentation technologies for pharmaceutical process research (Merck & Co.). Dr. Welch has authored more than 250 scientific publications and patents. He is co-founder of the journal, Enantiomer, a member of the editorial advisory board for the journals, Chirality, Journal of the Korean Chemical Society, Chemistry World and ACS Central Science. He has received honors and awards including the NJCG Award for Excellence in Chromatography, the PACS Activated Carbon Hall of Fame award, Merck Research Laboratories Presidents Award for Environmental Achievement, Microsoft Life Science Innovation Award, Fellow of the American Chemical Society, Fellow of the American Association for the Advancement of Science, the Chirality Medal, the University of Nebraska Chemistry Industrial Award and the EAS Award for Outstanding Achievement in Separation Science.
Stephen L. Buchwald, PhD
Steve Buchwald is the Camille Dreyfus Professor of Chemistry at the Massachusetts Institute of Technology (MIT) and is an expert in new chemical reaction methodology/development. His academic career has spanned over thirty years, during which he has co-authored over 420 academic publications and has 44 issued patents. His numerous honors and awards include the 2013 Arthur C. Cope Award from the American Chemical Society, the 2014 Linus Pauling Medal Award, and the 2014 BBVA Foundation Frontiers of Knowledge Award in Basic Sciences (awarded in 2015). He was elected as a fellow of the American Academy of Arts and Sciences in 2000 and as a member of the National Academy of Sciences in 2008. Professor Buchwald also serves as a scientific consultant to many companies and is an associate editor of Advanced Synthesis & Catalysis.
Andrea Adamo, PhD
Andrea Adamo is the CEO of Zaiput Flow Technologies — a leading continuous flow equipment design/manufacturing firm — and an entrepreneur with extensive experience in the development of innovative engineering solutions. Dr. Adamo holds a Master of Science in Engineering from the University of Palermo, Italy and a Ph.D. in Fluid Mechanics from the University Federico II of Naples, Italy, in addition to a Master of Science from the Massachusetts Institute of Technology (MIT). He was also awarded a Fulbright Scholarship. After completing his graduate studies, Dr. Adamo joined the laboratory of Professor Klavs Jensen, in MIT’s Chemical Engineering Department. He worked in the Jensen Group first as a post-doctoral associate and then as a research associate. In these positions, Dr. Adamo gained extensive experience in the design and manufacturing of innovative microfluidic and millifluidic systems.
Snapdragon Chemistry’s main focus is to deliver value to our clients. Thus, we have partnered with trusted, cutting-edge organizations that complement our skill sets and services, to provide the best solutions to our clients.
Asymchem (stock code: 002821.SZ) is a leading global integrated CDMO service provider of innovative drug R&D and manufacturing with 5000 employees based in China, the US, and the EU.
The combination of Snapdragon's technology and process development capabilities, along with Asymchem's expertise in clinical and commercial manufacturing provides our clients with a complete solution to drug development.
Zaiput Flow Technologies
Zaiput Flow Technologies is dedicated to bringing innovative tools for continuous flow to the market. Zaiput specializes in modular liquid-liquid separators and back pressure regulators for a variety of flow rates and with robust designs for harsh chemistries.
Through our partnership with Zaiput Flow Technologies, we will bring the most innovative and effective continuous flow technology to our clients. Zaiput and Snapdragon Chemistry are co-located in the Boston area, enabling us to collaborate efficiently to build cutting-edge reactor systems for continuous flow synthesis.
Paraza Pharma, Inc
Paraza Pharma, Inc. is an innovative company with an aim to improve significantly the efficiency of the drug discovery process from lead identification through lead optimization to development candidates.
Paraza complements Snapdragon Chemistry’s expertise in drug discovery and enables us to provide more holistic, innovative solutions to our clients in the discovery and early development space. Our combined insights, experience, and workforce help power an integrated solution that can completely transform productivity in discovery.
Usher III Initiative
The Usher III Initiative is a non-profit organization dedicated to finding therapies for patients with Usher syndrome type III, a rare genetic disorder that causes the progressive loss of both hearing and sight. Although typically born with normal vision and hearing, by mid-life, those afflicted with this devastating orphan disease are profoundly deaf and legally blind. For the past 17 years, the Initiative has focused on collaborative, therapy-directed, academic and industry research projects to investigate the cause of and a cure for Usher III. Through these efforts, the Initiative has discovered a proprietary compound, currently being manufactured in partnership with Snapdragon Chemistry, which will be developed as a potential treatment. With Snapdragon’s help, the Initiative is closer than ever to achieving its goal!